1900, 61, [2] leaves of plates
Book
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 19, pp. 1800 - 1808
In a randomized trial, patients with cardiovascular risk factors but no history of myocardial infarction were assigned to receive n−3 fatty acids or placebo....
MEDICINE, GENERAL & INTERNAL | Primary Prevention | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Hospitalization | Treatment Failure | General Practice | Cardiovascular Diseases - mortality | Fatty Acids, Omega-3 - therapeutic use | Female | Aged | Fatty Acids, Omega-3 - adverse effects | Prevention | Complications and side effects | Cardiovascular diseases | Health aspects | Risk factors | Omega-3 fatty acids | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | Polyunsaturated fatty acids | Mortality | Clinical trials | Cardiovascular disease | Olive oil | Angina pectoris | Patients | Fatty acids | Morbidity | Disease prevention | Vascular diseases | Arteriosclerosis | Patient safety | Heart diseases
MEDICINE, GENERAL & INTERNAL | Primary Prevention | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Hospitalization | Treatment Failure | General Practice | Cardiovascular Diseases - mortality | Fatty Acids, Omega-3 - therapeutic use | Female | Aged | Fatty Acids, Omega-3 - adverse effects | Prevention | Complications and side effects | Cardiovascular diseases | Health aspects | Risk factors | Omega-3 fatty acids | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | Polyunsaturated fatty acids | Mortality | Clinical trials | Cardiovascular disease | Olive oil | Angina pectoris | Patients | Fatty acids | Morbidity | Disease prevention | Vascular diseases | Arteriosclerosis | Patient safety | Heart diseases
Journal Article
Food Research International, ISSN 0963-9969, 02/2018, Volume 104, pp. 59 - 68
In recent years, there has been an explosion in the amount of available information on cancer in parallel with an ever-increasing number of cancer survivors....
Cancer survivors | Dietary changes | Cancer patients | Nutrition education | Food habits | Eating habits survey | Health information | DIAGNOSIS | METAANALYSIS | FOOD SCIENCE & TECHNOLOGY | CHEMOTHERAPY | BREAST-CANCER | SUPPLEMENT USE | COMPLEMENTARY THERAPIES | FAT | PHYSICAL-ACTIVITY | NUTRITION | SURVIVORS
Cancer survivors | Dietary changes | Cancer patients | Nutrition education | Food habits | Eating habits survey | Health information | DIAGNOSIS | METAANALYSIS | FOOD SCIENCE & TECHNOLOGY | CHEMOTHERAPY | BREAST-CANCER | SUPPLEMENT USE | COMPLEMENTARY THERAPIES | FAT | PHYSICAL-ACTIVITY | NUTRITION | SURVIVORS
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2009, Volume 360, Issue 16, pp. 1606 - 1617
In a randomized trial, 1442 patients with a history of atrial fibrillation were assigned to receive either valsartan, an angiotensin II–receptor blocker, or...
STROKE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | LEFT-VENTRICULAR DYSFUNCTION | SOLVD TRIALS | ACUTE MYOCARDIAL-INFARCTION | II RECEPTOR BLOCKADE | ANGIOTENSIN-II | PROGNOSTIC-SIGNIFICANCE | CONGESTIVE-HEART-FAILURE | SINUS RHYTHM | Recurrence | Prospective Studies | Double-Blind Method | Valsartan | Atrial Fibrillation - drug therapy | Comorbidity | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Valine - analogs & derivatives | Proportional Hazards Models | Cardiomegaly - epidemiology | Male | Atrial Fibrillation - epidemiology | Diabetes Mellitus - epidemiology | Cardiovascular Diseases - epidemiology | Female | Tetrazoles - therapeutic use | Valine - therapeutic use | Aged | Atrial Fibrillation - prevention & control | Prevention | Usage | Drug therapy | Health aspects | Atrial fibrillation | Studies | Cardiac arrhythmia | Cardiovascular disease
STROKE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | LEFT-VENTRICULAR DYSFUNCTION | SOLVD TRIALS | ACUTE MYOCARDIAL-INFARCTION | II RECEPTOR BLOCKADE | ANGIOTENSIN-II | PROGNOSTIC-SIGNIFICANCE | CONGESTIVE-HEART-FAILURE | SINUS RHYTHM | Recurrence | Prospective Studies | Double-Blind Method | Valsartan | Atrial Fibrillation - drug therapy | Comorbidity | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Valine - analogs & derivatives | Proportional Hazards Models | Cardiomegaly - epidemiology | Male | Atrial Fibrillation - epidemiology | Diabetes Mellitus - epidemiology | Cardiovascular Diseases - epidemiology | Female | Tetrazoles - therapeutic use | Valine - therapeutic use | Aged | Atrial Fibrillation - prevention & control | Prevention | Usage | Drug therapy | Health aspects | Atrial fibrillation | Studies | Cardiac arrhythmia | Cardiovascular disease
Journal Article
European Heart Journal, ISSN 0195-668X, 8/2007, Volume 28, Issue 16, pp. 1977 - 1983
Aims Controversy exists with regard to the influence of APOE polymorphisms on coronary heart disease development and on the efficacy of statin treatment. We...
Myocardial infarction | Genetics | Pharmacogenetics | Apolipoproteins | Survival | Statins | REDUCTASE INHIBITORS | GEMFIBROZIL | apolipoproteins | CARDIAC & CARDIOVASCULAR SYSTEMS | E GENOTYPES | CHOLESTEROL | myocardial infarction | survival | ATHEROSCLEROSIS | RISK | LIPOPROTEIN RESPONSE | genetics | statins | DISEASE | SIMVASTATIN | pharmacogenetics | Myocardial Infarction - genetics | Myocardial Infarction - mortality | Follow-Up Studies | Humans | Middle Aged | Genotype | Male | Treatment Outcome | Polymorphism, Genetic | Myocardial Infarction - drug therapy | Apolipoproteins E - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Female | Heterozygote | Pravastatin - therapeutic use
Myocardial infarction | Genetics | Pharmacogenetics | Apolipoproteins | Survival | Statins | REDUCTASE INHIBITORS | GEMFIBROZIL | apolipoproteins | CARDIAC & CARDIOVASCULAR SYSTEMS | E GENOTYPES | CHOLESTEROL | myocardial infarction | survival | ATHEROSCLEROSIS | RISK | LIPOPROTEIN RESPONSE | genetics | statins | DISEASE | SIMVASTATIN | pharmacogenetics | Myocardial Infarction - genetics | Myocardial Infarction - mortality | Follow-Up Studies | Humans | Middle Aged | Genotype | Male | Treatment Outcome | Polymorphism, Genetic | Myocardial Infarction - drug therapy | Apolipoproteins E - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Female | Heterozygote | Pravastatin - therapeutic use
Journal Article
FEMS Microbiology Ecology, ISSN 0168-6496, 04/2011, Volume 76, Issue 1, pp. 133 - 144
Abstract Studies suggesting that the development of atopy is linked to gut microbiota composition are inconclusive on whether dysbiosis precedes or arises from...
Gut microbiota | staphylococci | cow's milk allergy | allergic symptoms | murine model | germ‐free mouse | Staphylococci | Cow's milk allergy | Allergic symptoms | Germ-free mouse | Murine model | IGE | MICROBIOLOGY | germ-free mouse | COLONIZATION | MECHANISMS | BETA-LACTOGLOBULIN | ATOPIC-DERMATITIS | RESPONSES | STAPHYLOCOCCUS-AUREUS | FECAL MICROFLORA | ORAL SENSITIZATION | Chymases - blood | DNA, Bacterial - isolation & purification | Spleen - immunology | Immunoglobulin G - blood | Milk Hypersensitivity - blood | Chymases - immunology | Spleen - cytology | Cecum - microbiology | Milk Hypersensitivity - immunology | Immunoglobulin E - blood | Mice, Inbred C3H | Feces - microbiology | Animals | Immunoglobulin E - immunology | Milk Proteins - immunology | Cattle | Immunoglobulin G - immunology | Lactoglobulins - pharmacology | Germ-Free Life | Mice | Whey Proteins | Metagenome - immunology | Cecum - immunology | Disease Models, Animal | Milk proteins | Proteases | Analysis | Immunoglobulin G | Immunoglobulin E | Milk allergy | Cholera toxin | Food allergies | Allergies | Milk
Gut microbiota | staphylococci | cow's milk allergy | allergic symptoms | murine model | germ‐free mouse | Staphylococci | Cow's milk allergy | Allergic symptoms | Germ-free mouse | Murine model | IGE | MICROBIOLOGY | germ-free mouse | COLONIZATION | MECHANISMS | BETA-LACTOGLOBULIN | ATOPIC-DERMATITIS | RESPONSES | STAPHYLOCOCCUS-AUREUS | FECAL MICROFLORA | ORAL SENSITIZATION | Chymases - blood | DNA, Bacterial - isolation & purification | Spleen - immunology | Immunoglobulin G - blood | Milk Hypersensitivity - blood | Chymases - immunology | Spleen - cytology | Cecum - microbiology | Milk Hypersensitivity - immunology | Immunoglobulin E - blood | Mice, Inbred C3H | Feces - microbiology | Animals | Immunoglobulin E - immunology | Milk Proteins - immunology | Cattle | Immunoglobulin G - immunology | Lactoglobulins - pharmacology | Germ-Free Life | Mice | Whey Proteins | Metagenome - immunology | Cecum - immunology | Disease Models, Animal | Milk proteins | Proteases | Analysis | Immunoglobulin G | Immunoglobulin E | Milk allergy | Cholera toxin | Food allergies | Allergies | Milk
Journal Article
2012, 2nd ed., ISBN 9789814366601, xvi, 367 p., [3] p. of plates
Book
European Heart Journal, ISSN 0195-668X, 08/2007, Volume 28, Issue 15, p. 1977
AIMS: Controversy exists with regard to the influence of APOE polymorphisms on coronary heart disease development and on the efficacy of statin treatment. we...
Journal Article
LANCET, ISSN 0140-6736, 05/1994, Volume 343, Issue 8906, pp. 1115 - 1122
GISSI-3 is a multicentre randomised clinical trial to assess the efficacy of lisinopril, transdermal glyceryl trinitrate (GTN), and their combination in...
SURVIVAL | HEART | MEDICINE, GENERAL & INTERNAL | EXPANSION | VOLUME | DYSFUNCTION | ECHOCARDIOGRAPHY | DILATATION | CAPTOPRIL | Evaluation | Lisinopril | Drug therapy | Nitroglycerin | Heart attack | Medical research | Cardiovascular disease
SURVIVAL | HEART | MEDICINE, GENERAL & INTERNAL | EXPANSION | VOLUME | DYSFUNCTION | ECHOCARDIOGRAPHY | DILATATION | CAPTOPRIL | Evaluation | Lisinopril | Drug therapy | Nitroglycerin | Heart attack | Medical research | Cardiovascular disease
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2018, Volume 94, pp. 126 - 137
Troponin changes over time have been suggested to allow for an early diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin...
Clinical trial | Anthracyclines | Troponin | Cancer chemotherapy | Cardiotoxicity | Enalapril | HEART-FAILURE | DOXORUBICIN | INDUCED CARDIOMYOPATHY | CANCER-THERAPY | TROPONIN-I | BIOMARKERS | CONVERTING-ENZYME-INHIBITOR | ONCOLOGY | ADRIAMYCIN | HIGH-DOSE CHEMOTHERAPY | DYSFUNCTION | Anthracyclines - adverse effects | Cardiotoxicity - blood | Humans | Middle Aged | Male | Troponin C - blood | Enalapril - therapeutic use | Ventricular Dysfunction, Left - chemically induced | Ventricular Dysfunction, Left - prevention & control | Neoplasms - drug therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Ventricular Dysfunction, Left - blood | Antineoplastic Agents - adverse effects | Adult | Female | Aged | Cardiotoxicity - prevention & control | Clinical trials | Index Medicus
Clinical trial | Anthracyclines | Troponin | Cancer chemotherapy | Cardiotoxicity | Enalapril | HEART-FAILURE | DOXORUBICIN | INDUCED CARDIOMYOPATHY | CANCER-THERAPY | TROPONIN-I | BIOMARKERS | CONVERTING-ENZYME-INHIBITOR | ONCOLOGY | ADRIAMYCIN | HIGH-DOSE CHEMOTHERAPY | DYSFUNCTION | Anthracyclines - adverse effects | Cardiotoxicity - blood | Humans | Middle Aged | Male | Troponin C - blood | Enalapril - therapeutic use | Ventricular Dysfunction, Left - chemically induced | Ventricular Dysfunction, Left - prevention & control | Neoplasms - drug therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Ventricular Dysfunction, Left - blood | Antineoplastic Agents - adverse effects | Adult | Female | Aged | Cardiotoxicity - prevention & control | Clinical trials | Index Medicus
Journal Article